Amlodipine/azilsartan

Drug Profile

Amlodipine/azilsartan

Alternative Names: Amlodipine besylate/azilsartan FDC - Takeda; Azilsartan/amlodipine; Azilsartan/amlodipine besylate; TAK-536/amlodipine; TAK-536CCB; Zacras

Latest Information Update: 11 Jul 2016

Price : $50

At a glance

  • Originator Takeda
  • Class Antihypertensives; Benzimidazoles; Dihydropyridines; Oxadiazoles; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 01 Nov 2014 Phase-III clinical trials in Hypertension (Combination therapy) in Japan (PO) (NCT02277691)
  • 27 Oct 2014 Takeda plans a phase III trial for Essential hypertension (Combination therapy) in Japan (NCT02277691)
  • 18 Jun 2014 Launched for Hypertension in Japan (PO) - First global launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top